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Abstract
Background: Genome-wide RNAi screening has been widely used to identify host proteins involved in replication
and infection of different viruses, and numerous host factors are implicated in the replication cycles of these viruses,
demonstrating the power of this approach. However, discrepancies on target identification of the same viruses by
different groups suggest that high throughput RNAi screening strategies need to be carefully designed, developed
and optimized prior to the large scale screening.
Methods: Two genome-wide RNAi screens were performed in parallel against the entry of pseudotyped Marburg
viruses and avian influenza virus H5N1 utilizing an HIV-1 based surrogate system, to identify host factors which are
important for virus entry. A comparative analysis approach was employed in data analysis, which alleviated
systematic positional effects and reduced the false positive number of virus-specific hits.
Results: The parallel nature of the strategy allows us to easily identify the host factors for a specific virus with a
greatly reduced number of false positives in the initial screen, which is one of the major problems with high
throughput screening. The power of this strategy is illustrated by a genome-wide RNAi screen for identifying the
host factors important for Marburg virus and/or avian influenza virus H5N1 as described in this study.
Conclusions: This strategy is particularly useful for highly pathogenic viruses since pseudotyping allows us to
perform high throughput screens in the biosafety level 2 (BSL-2) containment instead of the BSL-3 or BSL-4 for the
infectious viruses, with alleviated safety concerns. The screening strategy together with the unique comparative
analysis approach makes the data more suitable for hit selection and enables us to identify virus-specific hits with a
much lower false positive rate.
Background
Emerging and re-emerging human viral pathogens pose
one of the major public health concerns since effective
countermeasures are not available to detect, prevent,
and treat these viral diseases [1]. The 2013–2015 West
Africa Ebola epidemic, with more than 25,000 people in-
fected and more than 12,000 deaths, underlines the glo-
bal challenge dealing with the infection and diseases
associated with these viruses. To develop prophylactic
and therapeutic options, it is important to understand
how these viruses interact with their hosts. Therefore ef-
forts have been made to identify and characterize host fac-
tors which are involved in viral replication and infection
for different viruses. A recently developed technology, re-
ferred to as genome-wide RNA interference (RNAi) based
screening [2], has been employed by different groups to
identify host factors systematically, and a large number of
host factors have been implicated as critical for infection
for viruses such as human immunodeficiency virus-1
(HIV-1 [3–5]) and influenza H1N1 virus [6–9], providing
mechanistic insights on the virus/host interactions.
However, the hit overlaps between screens by different
groups are pretty low, with 3–6 % for HIV-1 screens and
1–12 % for influenza virus screens [10], raising concerns
about the potential high false positive rates and even some
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skepticism on the utility of this technology. Thus, to avoid
potential screening artifacts and other issues, it is prudent
to carefully design high throughput RNAi screening strat-
egies and to optimize the parameters in the pilot experi-
ments prior to the large-scale screens.
Another obstacle in working with highly pathogenic
viruses is that they require high containment facilities
(biosafety level-3 or 4, or BSL-3 or BSL-4), which are
not readily available for many researchers. However this
problem can be often circumvented by an HIV-1 based
surrogate system in the entry studies and in the drug
discovery efforts to identify and develop antivirals target-
ing the entry process [11–17]. This HIV-1 based surro-
gate assay is particularly amenable for high throughput
screens because it is safe and robust. In this report, we
describe a genome-wide RNAi high throughput screen
strategy, referred to as parallel genome-wide RNAi
screen, which allows us to quickly identify host factors
important for the entry process of highly pathogenic vi-
ruses. This strategy was used for an RNAi screen to
identify host proteins specific for the entry process of
Marburg virus (MARV) or avian influenza virus H5N1
(AIV), demonstrating the utility of this approach.
Results
Development of a parallel genome-wide RNAi screen
protocol
To perform a high throughput RNAi screen to identify
the host factors involved in viral entry of highly patho-
genic Marburg virus and avian influenza virus H5N1,
which require BSL-3 and BSL-4 facilities, respectively,
we adopted a surrogate system which allows us to per-
form the initial screening in a BSL-2 facility [18]. This
human immunodeficiency virus-1 (HIV-1) based surro-
gate assay has been widely used by us and others to in-
vestigate the entry mechanisms of highly pathogenic
enveloped viruses such as filoviruses [11, 12, 16] (Ebola
and Marburg viruses), avian influenza virus H5N1 [13],
and severe acute respiratory syndrome coronavirus
(SARS-CoV) [19]. It has also been used to identify and
develop entry inhibitors as antivirals [14, 15].
In this study, avian influenza virus H5N1 pseudovir-
ions (AIV [13]) and Marburg virus pseudovirions
(MARV [20]) were generated and used in the genome
wide RNAi screen, as described in the Materials and
Methods. The basic principle of this surrogate assay is
based on the following two aspects: (1) AIV and MARV
viral envelope glycoproteins (HA and GP, respectively)
are necessary and sufficient to mediate virus entry, and
(2) these glycoproteins can be efficiently incorporated
into HIV-1 viral particles. Therefore these pseudovirions
retain the entry property dictated by avian influenza
virus H5N1 glycoprotein (HA) or Marburg glycoprotein
(GP). Thus, aspects of these entry mechanisms can be
evaluated despite of the surrogate nature of the viral par-
ticles. Furthermore, the pseudovirions carry a luciferase
reporter gene which can be used to measure the entry
activity of AIV and MARV [18].
The overall RNAi screening protocol is outlined in
Fig. 1. The key feature of the protocol is that AIV and
Fig. 1 Experimental design of the parallel genome-wide RNAi screen. A549 cells are reverse transfected with siRNAs in two 384-well plates in
parallel. After 48 h incubation, cells in one plate are challenged by Marburg pseudovirions and the cells in the other plate are challenged by
influenza H5N1 pseudovirions. The virions are removed 24 h later and the cells are incubated with fresh medium for an additional 24 h. Virus infection
is then quantified by a luciferase activity assay. siRNA only showing low signal (black) in an assay plate of one virus is regarded as a virus specific hit;
siRNA showing low signals in assay plates of both viruses is regarded as a “shared” hit by the two viruses
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MARV pseudovirions were used in parallel in the RNAi
screen which allowed us to reduce the number of false
positives and to quickly identify Marburg-specific and
flu-specific host factors (which will be further discussed
below). Briefly, human A549 cells (~1000 cells/well)
were reverse transfected with 10nM small interfering
RNAs (siRNAs) in two identical 384-well plates simul-
taneously. These plates were incubated for 48 h for tar-
get gene expression knockdown, followed by challenging
one plate with AIV pseudovirions and the other plate
with MARV pseudovirions. Virions were replaced with
fresh medium 24 h post infection and the plates were in-
cubated for additional 24 h. Luciferase assays were then
performed to quantify virus infection.
Quality control of the screen
Screen data quality is crucial for subsequent data ana-
lysis and hit selection. Quality control of the screen is
commonly indicated by the Z’ factor [21] which assesses
the separation between measured signals of the positive
and negative controls in an assay plate.
In our screens, we included three controls: non-
targeting siRNA as the negative control and siRNAs tar-
geting luciferase or ATP6V0C as the positive controls.
The pseudovirion carries a luciferase reporter gene, and
AIV and MARV virus entry is dependent on the low-pH
environment in the endosome/lysosome which is regu-
lated by vacuolar ATPase. So siRNA targeting luciferase
or ATP6V0C (a component of vacuolar ATPase) is ex-
pected to significantly reduce the final luciferase activity
level. In addition, these two positive controls can serve
as transfection efficiency controls, monitoring siRNA
transfection. Eight control siRNAs of each type were ar-
ranged on the column 23 or 24 of a 384-well assay plate,
as shown in Fig. 2a.
Figure 2b represents the normalized signal distribu-
tions of the samples and the controls. The normalized
signal was obtained by dividing the measured signal in
each well by the median luciferase signal of all sample
wells in a plate. It is clear that both siRNAs targeting lu-
ciferase and ATP6V0C greatly reduced luciferase signal
level with little variance, confirming their efficacy and
excellent siRNA transfection efficiency in the screen.
The samples show a broad bell-shaped signal distribu-
tion, with a little positively skewed. The signal distribu-
tion of the non-targeting control was expected to
overlap with that of samples. However in our screen, this
distribution was shifted to the right, showing a higher
signal level. The skewed sample distribution and the
shift of negative control distribution suggest that the
assay plates were affected by edge effects or the pos-
itional effects (see below).
Despite of the adverse impact of the positional ef-
fects, the Z’s calculated from two control combinations
(luciferase versus non-targeting and ATP6V0C versus
non-targeting), are very close to 0.5, an indication of ex-
cellent assay quality (Fig. 2c). In comparison with Z’s from
AIV screen plates, Z’s from MARV screen plates exhibited
less favorable values and wider ranges, suggesting a larger
Fig. 2 Quality control of the screen. a Screen plate design. A
representative 384-well plate is shown to illustrate the locations of
sample and control siRNAs. Sample siRNAs (red) are arranged in
column 1 through column 22. Non-targeting siRNAs (blue) and siRNAs
targeting ATP6V0C (green) or luciferase (yellow) are arranged in
columns 23 and 24 respectively. b Signal distribution of samples and
controls. The sample and control luciferase signals are normalized by
the median signal value of all the samples in each 384-well assay plate.
The normalized signal distributions in both Marburg virus (MARV) and
influenza H5N1 virus (AIV) plates are plotted for sample (red) and
controls: ATP6V0C (green), luciferase (yellow) and non-targeting (blue).
c Z’ factors. Z’ factors are computed either by the normalized signal
values of luciferase and non-targeting controls (luc vs nt) or those of
ATP6V0C and non-targeting controls (atp6 vs nt). These Z’ factors are
plotted for both MARV and AIV plates
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variation in MARV screen data. This is consistent with
what is shown in Fig. 2b, that is that both samples and
non-targeting controls from MARV screen plates have
flatter signal distributions, as compared with those from
AIV screen plates.
Alleviation of positional effects by comparative data
analysis
In the aforementioned screen strategy, we were more in-
terested in identifying virus-specific host proteins which
could be revealed by a comparative analysis approach, due
to the parallel nature of the screen. In this approach, the
infection rates for AIV and MARV for each siRNA were
obtained respectively by normalizing the measured lucifer-
ase signals with corresponding plate signal medians; the
relative infection index, namely the logarithm of the ratio
of their infection rates to base 2 - log2(ratioMARV/AIV), was
then calculated for each siRNA to indicate specificity.
Theoretically, an siRNA with relative infection index
equaling to zero means no bias of the siRNA on the
infections of both viruses; an siRNA inhibiting MARV in-
fection or enhancing AIV infection results in a minus
value, and an siRNA with an the opposite effect results in
a positive value.
We used this comparative analysis as a means to cor-
rect the observed positional effects. The robust z-score,
a robust version of z-score which indicates the number
of standard deviations from the mean, was employed to
represent data variance. The robust z-score distributions
of the normalized signals for the columns and rows from
both AIV and MARV screen plates are shown in Fig. 3.
Consistent with what we show in Fig. 2b, the distribu-
tions from the columns and rows are skewed towards
the high z-score value area, with the outer two columns
and rows more severely affected. When the relative in-
fection index was introduced, the excess variations of
the peripheral positions were greatly reduced and the
distributions of columns and rows were corrected to be
more symmetrical. The same is true regarding the distri-
butions of the all siRNAs. As shown in Fig. 3 (the
Fig. 3 Comparative analysis reduces systematic positional effects. The normalized signals from Marburg virus (MARV) or influenza H5N1 virus (AIV)
plates are used to calculate the median and median absolute deviation (MAD) respectively. Relative infection index is first calculated by using
normalized signals from both virus plates and then it is used to compute the median and the MAD. The robust z-score for normalized signal or
the relative infection index is then computed for each well and the robust z-score distributions across all the rows or the columns or the plates
are plotted accordingly for AIV and MARV plates
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bottom panel), the robust z-scores of the normalized sig-
nals from both screens are heavily skewed to the right,
with almost no siRNAs showing robust z-score less
than −2, a recommended criterion for picking inhibitory
hits. The robust z-scores of the relative infection index,
however, are evenly distributed, reducing the skewed dis-
tribution caused by the positional effects and making the
data more suitable for the hit selection.
Hit selection
Since the relative infection index approach can reduce
the systematic errors, we combined it with the individual
virus infection rates to identify virus-specific host fac-
tors. As presented in Fig. 4a, the hit selection began with
normalizing the measured luciferase signals by the plate
signal medians for MARV and AIV, respectively. These
normalized scores were used for calculating the relative
infection index, from which a robust z-score was then
computed for each siRNA. Thresholds of ±2 were
adopted for filtering the hits. From the total 64,775
individual siRNAs, 3,036 siRNAs targeting 2,858 genes
had robust z-scores less than −2, while 2,409 siRNAs
targeting 2299 genes had robust z-scores greater than 2.
Another criterion (2 siRNAs per gene rule) that a gene
must have at least 2 siRNAs showing similar effects was
applied to further filter the hits, with the aim of reducing
false positive numbers. Accordingly, 173 genes with 351
siRNAs for MARV and 109 genes with 219 siRNAs for
AIV were selected, respectively. The individual virus infec-
tion rates (the normalized signals) were then employed as
a reference to distinguish an inhibitory hit from the one
that enhances virus infection. The robust z-scores are
plotted against normalized signals of each virus in Fig. 4b
and c. A robust z-score less than −2 in Fig. 4b means that
the MARV infection rate is much less than AIV infection
rate for the corresponding siRNA. This may be a result of
inhibited MARV infection or of enhanced AIV infection.
Thus a MARV score (normalized signal) below 0.5 was
used to indicate a MARV inhibitory hit, which is repre-
sented in area I in Fig. 4b. A gene with at least two
Fig. 4 Hit selection. a Flowchart of hit selection process. (b and c) Enrichment of hits. For each siRNA, the normalized signal from Marburg virus
(MARV) or influenza H5N1 virus (AIV) plates is plotted against the robust z-score of the relative infection index. Hits in area I are classified as
specific inhibitory hits against either MARV or AIV entry. Hits in area II are classified as non-specific inhibitory hits against either MARV or AIV
entry. Hits in area III are classified as hits that enhance virus entry of either MARV or AIV
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siRNAs’ MARV scores < 0.5 was used to filter the hits in
area I, with 106 genes being identified as host factors
that inhibit MARV entry. On the contrary, MARV
scores greater than 0.8, which means the siRNA has lit-
tle effect on inhibiting MARV infection, were used to
indicate a hit enhancing AIV entry. Area III in Fig. 4b
represents these hits and 4 host factors were identified
with the 2 siRNAs per gene rule. Similarly, area I in
Fig. 4c represents AIV inhibitory hits and 42 genes were
identified; area III represents the hits enhancing MARV
entry with 12 genes finally identified.
The use of relative infection index together with indi-
vidual virus infection rate and the 2 siRNAs per gene
rule is a powerful means to identify virus-specific host
factors and to reduce the false positive rate. The parallel
nature of the screen strategy makes the results from the
two viruses highly comparable and the relative infection
index obtained by comparison easily establishes virus-
specificity. As shown in Fig. 4b and c, only hits in areas I
and III were picked for further analysis. Though many
other siRNAs also showed inhibitory effects (area II), these
siRNAs were ruled out for lack of virus-specificity, greatly
reducing the false positive rate. Further, the 2 siRNAs per
gene rule helped to reduce false positive which may result
from off-target effects or systematic errors.
A selected short list of EBOV or AIV entry-related
genes is shown in Table 1 to demonstrate the power of
the parallel screen strategy described in this report. Four
of seven subunits of the coatomer 1 (COP-I) vesicular
transport complex (i.e., ARCN1, COPA, COPB2, and
COPG) were reported to be critical for influenza virus
replication by others [8], but only ARCN1 was identified
as an AIV-specific hit in this screen (Table 1). The other
three proteins were identified in our screen as “shared”
host factors for both AIV and MARV (data not shown).
Proton-transporting V-type ATPase was implicated as
the host factor for influenza virus infection by the previ-
ous screens [8], and we show that only two subunits of
ATPase, APT6V0C and ATP6AP2, are AIV-specific. A
number of other subunits (i.e. ATP6AP1, ATP6V0B,
ATP6V0D1, ATP6V1A and ATP6V1B2) are not specific
to AIV but are “shared” host factors by both viruses. As
for MARV, a few essential MARV-specific host factors
were identified by the screen in this study. Cathepsin L
(CTSL), which primes the filovirus glycoprotein in the
endosome [22], EXT1 [23], which is involved in biosyn-
thesis of heparan sulfate, and Niemann-Pick disease,
type C1 (NPC1 [24, 25]), showed strong bias against
MARV entry (Table 1). Also, HOPS complex, which
mediates fusion of the endosome and lysosome, was
identified as a host factor for Ebola virus infection in
a gene-trap based screen [24], and we identified VPS
16, a subunit of HOPS complex, as a MARV-specific
hit in the current screen.
It is interesting to note that two host proteins, FOLR1
[26] and TIM1 [27], which were previously reported as
host factors important for filovirus entry, were not iden-
tified as the hits in this study (Table 1). The results from
this report are consistent with a study which showed
that FOLR1 was not critical for filoviral entry [28]. How-
ever, more studies are needed to evaluate the potential
role of TIM1 in filoviral entry.
Discussion
This report describes a new strategy, referred to as a
parallel genome-wide RNAi screen, to identify host fac-
tors which are important for entry of enveloped viruses.
This strategy is particularly useful for highly pathogenic
viruses such as Ebola/Marburg viruses and avian influ-
enza virus H5N1 (or bird flu) since the HIV-1 based sur-
rogate system allows us to perform high throughput
screens in the biosafety level 2 (BSL-2) containment in-
stead of the BSL-4 or BSL-3 for the infectious viruses
with alleviated safety concerns. More importantly, the
parallel nature of the strategy allows us to easily identify
Table 1 A selected virus entry gene list from the parallel
genome-wide RNAi screen
siRNA #1 siRNA #2 siRNA #3
Gene Virus scorea rzscoreb score rzscore score rzscore
NPC1 MARV 0.32 −3.25 0.29 −3.35 0.22 −3.73
AIV 1.37 1.28 1.16
EXT1 MARV 0.22 −3.48 0.36 −2.98 0.87 −0.07
AIV 1.03 1.35 0.89
VPS16 MARV 0.26 −1.74 0.36 −2.31 0.11 −4.93
AIV 0.57 1.01 0.96
CTSL MARV 0.90 1.09 0.38 −1.82 0.11 −3.92
AIV 0.55 0.86 0.61
TIM1 MARV 2.06 1.21 1.33 −0.2 1.75 0.44
AIV 1.18 1.44 1.42
FOLR1 MARV 1.68 −0.33 0.57 0.46 0.45 0.36
AIV 1.93 0.46 0.38
ARCN1 MARV 1.17 4.71 0.03 −6.62 0.22 3.35
AIV 0.14 0.57 0.05
ATP6V0C MARV 0.27 1.32 0.11 2.03 0.26 3.53
AIV 0.15 0.04 0.05
ATP6V0D1 MARV 0.08 1.05 0.23 −1.59 0.04 3.93
AIV 0.05 0.47 0.23
ATP6AP1 MARV 0.16 0.80 0.57 −1.14 0.8 6.31
AIV 0.11 0.95 0.05
For each gene, three siRNAs are shown with their robust z-score of relative
infection index. siRNAs with positive values are putative influenza H5N1 virus
specific host factors; siRNAs with negative values are putative Marburg virus
specific host factors
ascore is normalized luciferase signal by plate median signal
brzscore is the robust zscore of relative infection index (log2RatioMARV/AIV)
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the host factors for a specific virus with a greatly re-
duced number of false positives in the initial screen,
which is one of the major problems with high through-
put screening. The power of this strategy is well illus-
trated by a genome-wide RNAi screen for identifying the
host factors important for MARV and/or AIV as de-
scribed in this study.
Genome-wide RNAi screening has been widely used to
identify host proteins involved in replication and infec-
tion of different viruses, and numerous host factors are
implicated in the replication cycles of these viruses,
demonstrating the power of this approach. However, it is
clear that these RNAi screens, even performed on the
same virus by different groups, do not always identify
the same set of host proteins, suggesting that high
throughput RNAi screening strategies need to be care-
fully developed and optimized prior to the actual screen-
ing. Thus several features of the screening strategy
described here are attractive to identify host proteins in-
volved in viral entry of highly pathogenic enveloped vi-
ruses. One obvious advantage of this strategy is that it
can distinguish virus-specific hits from the “shared” hits.
Because each virus in the screen also serves as a control
for the other virus, an siRNA showing effects on one
virus but not on the other one will be tentatively classi-
fied as a specific hit, as illustrated in Fig. 1. On the other
hand, if an siRNA shows similar inhibitory effects on
both viruses, the scenarios are more complicated: (1) the
siRNA may be toxic to the cells; (2) it may induce an
off-target effect; (3) it may target an HIV-1 related
process after the pseudovirion is released from the endo-
some/lysosome; (4) it may target the shared host factors
by both viruses (i.e. AIV and MARV in this study).
Another merit of the current strategy is that it can re-
duce the false positive rate. The reasons for high false
positive rates in a genome-wide RNAi screen are due to
a lack of replicates and siRNA off-target effects. In this
study, each siRNA was actually tested twice, but with
two different viruses. For an siRNA specific to one virus
entry, the possibility of obtaining similar results for two
different viruses is pretty low, greatly decreasing the false
positive rate. For shared hits, the false positive rate also
decreases owing to the duplicate nature of this strategy.
Further, an siRNA hit due to an off-target effect is likely
to affect both viruses' infection and can thus be classified
as a “shared” hit, resulting in a lower false positive rate
for the virus-specific hit. In addition, it has been recently
shown that virus infection rate is largely determined by
the population context (e.g. local cell density) of the tar-
get cell which can be affected by gene perturbations
through RNAi [29]. Because the screens in this study
were performed in parallel, the cell population context
was, to a large extent, the same for the two viruses, mak-
ing the results from the two screens highly comparable.
We have observed the position effects in this study,
which are a commonly observed phenomenon in RNAi
screens, as a result of the long incubation period needed
for RNAi assays. Thus it can bring more noise to the
screen and results in distortions of the true effects of
siRNAs. A number of pre and post-screening correction
methods have been developed to battle these effects. It
has been suggested that the controls evenly scattered
over an assay plate by careful plate design can be used
to adjust the systematic errors [30]. However, most com-
mercial available siRNA libraries only have the peripheral
wells reserved for controls; in our case, only the outer 23
and 24 columns are available for controls, leaving little
room for control-based systematic error adjustment. Also,
a few mathematical algorithms have been proposed to re-
duce the effects [31]. These methods usually assume a
large difference between a positive and a negative re-
sponse and the sparseness of positive responses, which is
not true for RNAi screens. In fact, RNAi is a very compli-
cated biological phenomenon; even an siRNA targeting an
unrelated gene may induce somewhat positive phenotype.
Thus modifying the original screen data with additional
correction factors by those proposed mathematical treat-
ment may lead to more man-made artifacts.
In our comparative analysis approach, however, we are
able to alleviate the positional effects without introdu-
cing a correction factor. The positional effects are largely
due to the different evaporation rates across the plate
which leads to a multiplicative bias to the measured sig-
nal. Because the screens were performed in parallel, the
duplicate wells with a same relative position in two
plates were screened simultaneously, making them sub-
ject to a similar positional effect. This multiplicative bias
can thus be corrected by simply dividing virus infection
rate by the rate of the other one. In our case, the relative
infection index was used to reduce the bias and the re-
sults we presented in Fig. 3 have clearly validated this
approach.
It should be pointed out that this report describes a
powerful high throughput screening strategy which al-
lows the initial identification of host proteins which may
play a role in AIV- or MARV-specific entry. However,
the role of each putative host factor has to be individu-
ally confirmed and validated, and one of the challenges
is to prioritize and select the host factors to be carefully
characterized.
Conclusions
We have developed a parallel genome-wide RNAi screen
strategy to identify specific host factors to either AIV or
MARV entry. Implementation of this strategy generated
two sets of data and a comparative analysis approach is
proposed. Our screening strategy together with the unique
comparative analysis approach alleviates the systematic
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positional effects, makes the data more suitable for hit se-
lection, and enables us to pick virus-specific hits with a
much lower false positive rate. This strategy, we believe,
can be easily adapted to other screens with the aim of in-
creasing screen specificity and reducing false positive rates.
Methods
Cell culture and plasmids
Human 293 T embryonic kidney cells and human lung
epithelial A549cells were cultured in Dulbecco's modified
Eagle's medium (DMEM, Cellgro) supplemented with
10 % fetal bovine serum (FBS, Gibco), 100 μg/mL of
streptomycin and 100 units of penicillin (Invitrogen). The
avian influenza virus H5N1/HIV pseudovirions (AIV) and
Marburg virus/HIV pseudovirions (MARV) were gener-
ated from the following plasmids: hemagglutinin (HA),
isolated from a highly pathogenic avian influenza virus, A/
Goose/Qinghai/59/05 (H5N1) [13]; neuraminidase (NA)
from A/Puerto Rico/8/1934 (H1N1) [13]; Marburg virus
glycoprotein GP (MGP) [20]. The HIV-1 proviral vector
pNL4-3.Luc.R−E− [32, 33] was obtained through the NIH
AIDS Research and Reference Reagent program.
Production of pseudovirions
AIV and MARV pseudovirions were produced by transient
co-transfection of human 293 T cells using a polyethyleni-
mine (PEI)-based transfection protocol [11]. Replication-
defective HIV vector (pNL4-3.Luc.R−E−) together with
plasmids encoding MGP or HA/NA were used for transi-
ent co-transfection into 293 T producer cells. Six hours
after transfection, cells were washed with phosphate-
buffered saline (PBS), and 40 mL of fresh medium was
added to each plate (150 mm). Forty-eight hours post
transfection, the supernatants were collected and filtered
through 0.45 μm pore size filter (Nalgene). The pseudovir-
ion stocks were stored at 4 °C prior to use.
siRNA libraries and controls
Three siRNA libraries (Silencer® Select Human Druggable
Genome siRNA Library V4, Human Druggable Genome
V4 Extension and Human Genome V4 siRNA Extension)
were purchased from Ambion (Austin, TX). These librar-
ies contain 64,755 siRNAs targeting 21,585 human genes
(each gene has three distinct siRNAs). Daughter plates
were prepared in 384-well format at a 250nM concentra-
tion in water. Controls include siRNA targeting ATP6V0C
or luciferase and non-targeting siRNA. All control siRNAs
were purchased from Ambion.
Genome-wide RNAi screening
All siRNAs were arrayed in 384-well plates. For each assay
plate well, 2 μl siRNA was mixed with 0.1 μl Lipofectamine
RNAiMAX (Invitrogen) and 9.9 μl Opti-MEM (Invitrogen).
After 20 min incubation at room temperature, 38 μl cell
suspension of 1000 A549 cells was added, resulting in a
final siRNA concentration of 10nM. Cells were incubated
at 37 °C and 5 % CO2 for 48 h. Then the medium was re-
moved and the cells were challenged with 30 μl MARV or
AIV virions in parallel. Virions were removed 24 h later
and 30 μl fresh DMEM supplemented with FBS and antibi-
otics was added to each well. After another 24 h incubation,
15 μl of neolite luciferase substrate (PerkinElmer, Waltham,
MA) was mixed in, incubated for 5 min, and lucifer-
ase activity was measured with an Envision plate
reader (PerkinElmer). All multi-well pipetting proce-
dures were conducted by the JANUS automated li-
quid handling system (PerkinElmer).
Data analysis
The measured luminescence signal was analyzed using
the statistical programming language R. The signal in
each well was first normalized by the median value of all
the samples from the same plate.
The Z’ factor [21] was calculated from the normalized
signals of not-targeting and ATP6V0C controls or from
those of not-targeting and luciferase controls on each plate
with the following equation: Z ' = 1 − 3(Stdhigh ‐ signal +
Stdlow ‐ signal)/(Meanhigh ‐ signal −Meanlow ‐ signal).
For each siRNA, the relative infection index was calcu-
lated from the corresponding normalized signals from
the MARV and AIV plates with the following equation:
relative infection index = log2 (normalized signalMARV/
normalized signalAIV).
Robust z-score was calculated for both normalized sig-
nal and relative infection index. First, median absolute
deviation (MAD [34]) was calculated as follows:
MAD ¼ 1:4826median xij−median xð Þ
  ;
and then the robust z-score was calculated for each
siRNA as follows:
robust z‐score ¼ xij‐median xð Þ
 
=MAD;
where x represents the set of all the normalized signals
or the relative infection indexes of the samples and xij
indicates the value for a particular well at row i and col-
umn j. The constant 1.4826 is used to make MAD com-
parable to standard deviation.
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